<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2026-15-2-2076</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-2333</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL TECHNOLOGY</subject></subj-group></article-categories><title-group><article-title>Применение рискориентированного подхода для определения критических параметров процесса получения лиофилизата на основе производного ЛХС-1269</article-title><trans-title-group xml:lang="en"><trans-title>Application of a risk-based approach to determine critical parameters of the process of obtaining a lyophilisate based on a derivative of LCS-1269</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0650-2023</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ланцова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lantsova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>23, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5592-5137</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Санарова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sanarova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>23, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4558-0083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орлова</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Orlova</surname><given-names>O. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>23, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9388-1019</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колпаксиди</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolpaksidi</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>23, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6986-3942</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Оборотова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Oborotova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>23, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8003-8241</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаева</surname><given-names>Л. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaeva</surname><given-names>L. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 23; 119048, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>23, Kashirskoe shosse, Moscow, 115522; 8/2, Trubetskaya str., Mosсow, 119048</p></bio><email xlink:type="simple">alima91@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3034-750X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шпрах</surname><given-names>З. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shprakh</surname><given-names>Z. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, г. Москва, Каширское шоссе, д. 23</p></bio><bio xml:lang="en"><p>23, Kashirskoe shosse, Moscow, 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России.)<country>Россия</country></aff><aff xml:lang="en">Federal State Budgetary Institution "N. N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ онкологии им. Н. Н. Блохина» Минздрава России); Федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И. М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)<country>Россия</country></aff><aff xml:lang="en">Federal State Budgetary Institution "N. N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian; I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University)<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>03</day><month>04</month><year>2026</year></pub-date><volume>0</volume><issue>0</issue><issue-title>Принято в печать</issue-title><elocation-id>2333</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Ланцова А.В., Санарова Е.В., Орлова О.Л., Колпаксиди А.П., Оборотова Н.А., Николаева Л.Л., Шпрах З.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Ланцова А.В., Санарова Е.В., Орлова О.Л., Колпаксиди А.П., Оборотова Н.А., Николаева Л.Л., Шпрах З.С.</copyright-holder><copyright-holder xml:lang="en">Lantsova A.V., Sanarova E.V., Orlova O.L., Kolpaksidi A.P., Oborotova N.A., Nikolaeva L.L., Shprakh Z.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/2333">https://www.pharmjournal.ru/jour/article/view/2333</self-uri><abstract><sec><title>Введение</title><p>Введение. Сохранение основных параметров качества лекарственного средства (ЛС) – залог его успешного применения в клинической практике. Продуктивное использование результатов выявления и оценки рисков позволяет гарантировать эффективность и безопасность ЛС за счет предупредительных мер по выявлению и устранению потенциальных угроз для качества при его разработке и производстве.</p></sec><sec><title>Цель</title><p>Цель. Цель исследования – выявление критических точек технологического процесса получения лиофилизированной лекарственной формы соединения из класса индолокарбазолов ЛХС-1269 с использованием рискориентированного подхода.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Для анализа рисков в технологии получения лиофилизата на основе ЛХС-1269 применяли инструменты и методы анализа управления рисками, представленные в руководствах ICH Q8, Q9, Q10, Государственной фармакопеи РФ XV изд. и ГОСТР ИСО 31000-2019.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. При идентификации рисков производственного процесса выявлены основные критические параметры процесса и критические контрольные точки, среди которых наибольшее значение оказывают соблюдение режима растворения фармацевтической субстанции и вспомогательных веществ, фильтрации полученного раствора и его лиофилизации, а также контроль по основным показателям качества, характерным для лиофилизатов для парентерального применения.</p></sec><sec><title>Заключение</title><p>Заключение. Применение выбранного подхода позволило выявить и оценить возможные риски для качества продукции на разных стадиях производства ЛС «ЛХС-1269, лиофилизат для приготовления раствора для инъекций, 25 мг» и разработать стратегию по устранению или смягчению данных рисков и достижению необходимых целей, а именно получения качественного, эффективного и безопасного ЛС.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Maintaining the basic quality parameters of a drug is the key to its successful use in clinical practice. Productive use of the results of risk identification and assessment allows us to guarantee the effectiveness and safety of medicines through preventive measures to identify and eliminate potential threats to quality during their development and production.</p></sec><sec><title>Aim</title><p>Aim. The aim of the study was to identify critical points in the technological process of obtaining a lyophilized dosage form of a compound from the class of indolocarbazoles LCS-1269 using a risk-based approach.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. To analyze the risks in the technology for obtaining a lyophilisate based on LCS-1269, the risk management analysis tools and methods presented in the ICH Q8, Q9, Q10, State Pharmacopoeia of Russia XV ed. and ISO 31000-2019 guidelines were used.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. When identifying risks of the production process, the main critical process parameters and critical control points were identified, among which the most important are compliance with the mode of dissolution of the pharmaceutical substance and excipients, filtration of the resulting solution and its lyophilization, as well as control over the main quality indicators characteristic of lyophilized dosage forms for parenteral use.</p></sec><sec><title>Conclusion</title><p>Conclusion. The application of the selected approach made it possible to identify and assess possible risks to product quality at different stages of production of the drug "LCS-1269, lyophilisate for preparation of injection solution 25 mg" and to develop a strategy to eliminate or mitigate these risks and achieve the necessary goals, namely, obtaining high-quality, effective and safe drugs.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ЛХС-1269</kwd><kwd>лиофилизат</kwd><kwd>фармацевтическая разработка</kwd><kwd>анализ опасности</kwd><kwd>критические контрольные точки</kwd><kwd>критический параметр процесса</kwd></kwd-group><kwd-group xml:lang="en"><kwd>substance LCS-1269</kwd><kwd>lyophilisate</kwd><kwd>pharmaceutical development</kwd><kwd>hazard analysis</kwd><kwd>critical control points</kwd><kwd>critical process parameter</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Тишков С. В., Блынская Е. В., Алексеев К. В., Алексеев В. К. Аспекты управления рисками для качества в фармацевтической разработке. Вопросы биологической, медицинской и фармацевтической химии. 2023;26(3):3–10. DOI: 10.29296/25877313-2023-03-01.</mixed-citation><mixed-citation xml:lang="en">Tishkov S. V., Blynskaya E. V., Alekseev K. V., Alekseev V. K. Risk management aspects for quality in pharmaceutical development. Problems of biological, medical and pharmaceutical chemistry. 2023;26(3):3-10. (In Russ.) DOI: 10.29296/25877313-2023-03-01</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Srishti S. A., Pinky P. P., Taylor R., Guess J., Karlik N., Janjic J. M. Quality by Design (QbD)-Driven Development and Optimization of Tacrolimus-Loaded Microemulsion for the Treatment of Skin Inflammation. Pharmaceutics. 2024;16(12):1487. DOI: 10.3390/pharmaceutics16121487.</mixed-citation><mixed-citation xml:lang="en">Srishti S. A., Pinky P. P., Taylor R., Guess J., Karlik N., Janjic J. M. Quality by Design (QbD)-Driven Development and Optimization of Tacrolimus-Loaded Microemulsion for the Treatment of Skin Inflammation. Pharmaceutics. 2024;16(12):1487. DOI: 10.3390/pharmaceutics16121487.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tabibzadeh M., Muralidharan A. Reducing Medication Errors and Increasing Patient Safety: Utilizing the Fault Tree Analysis. In: Lightner N. J., editor. Advances in Human Factors and Ergonomics in Healthcare and Medical Devices. Cham: Springer; 2019. P. 207–218. DOI: 10.1007/978-3-319-94373-2_23.</mixed-citation><mixed-citation xml:lang="en">Tabibzadeh M., Muralidharan A. Reducing Medication Errors and Increasing Patient Safety: Utilizing the Fault Tree Analysis. In: Lightner N. J., editor. Advances in Human Factors and Ergonomics in Healthcare and Medical Devices. Cham: Springer; 2019. P. 207–218. DOI: 10.1007/978-3-319-94373-2_23.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Glevitzky M., Glevitzky I., Mucea-Ștef P., Popa M., Dumitrel G.-A., Vică M. L. Integrated Risk Framework (IRF) – Interconnection of the Ishikawa Diagram with the Enhanced HACCP System in Risk Assessment for the Sustainable Food Industry. Sustainability. 2025;17(2):536. DOI: 10.3390/su17020536.</mixed-citation><mixed-citation xml:lang="en">Glevitzky M., Glevitzky I., Mucea-Ștef P., Popa M., Dumitrel G.-A., Vică M. L. Integrated Risk Framework (IRF) – Interconnection of the Ishikawa Diagram with the Enhanced HACCP System in Risk Assessment for the Sustainable Food Industry. Sustainability. 2025;17(2):536. DOI: 10.3390/su17020536.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gehring K. B., Kirkpatrick R. Hazard analysis and critical controlpoints (HACCP). In: Demirci A., Feng H., Krishnamurthy K., editors. Food safety engineering. Cham: Springer; 2020. P. 191-204. DOI: 10.1007/978-3-030-42660-6_8.</mixed-citation><mixed-citation xml:lang="en">Gehring K. B., Kirkpatrick R. Hazard analysis and critical controlpoints (HACCP). In: Demirci A., Feng H., Krishnamurthy K., editors. Food safety engineering. Cham: Springer; 2020. P. 191-204. DOI: 10.1007/978-3-030-42660-6_8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lauri R., Incocciati E., Pietrangeli B., Tayou L. N., Valentino F., Gottardo M., Majone M. Hazop Analysis of a Bioprocess for Polyhydroxyalkanoate (PHA) Production from Organic Waste: Part B. Fermentation. 2023;9(2):154. DOI: 10.3390/fermentation9020154.</mixed-citation><mixed-citation xml:lang="en">Lauri R., Incocciati E., Pietrangeli B., Tayou L. N., Valentino F., Gottardo M., Majone M. Hazop Analysis of a Bioprocess for Polyhydroxyalkanoate (PHA) Production from Organic Waste: Part B. Fermentation. 2023;9(2):154. DOI: 10.3390/fermentation9020154.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Signoret J. P., Leroy A. Hazard and operability study (HAZOP). In: Signoret J.-P., Leroy A. Reliability assessment of safety and production systems: analysis, modelling, calculations and case studies. Cham: Springer; 2021. P. 157–164. DOI: 10.1007/978-3-030-64708-79.</mixed-citation><mixed-citation xml:lang="en">Signoret J. P., Leroy A. Hazard and operability study (HAZOP). In: Signoret J.-P., Leroy A. Reliability assessment of safety and production systems: analysis, modelling, calculations and case studies. Cham: Springer; 2021. P. 157–164. DOI: 10.1007/978-3-030-64708-79.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Блынская Е. В., Тишков С. В., Алексеев К. В., Минаев С. В. Особенности фармацевтической разработки лиофилизата ГК-2 для парентерального применения. Российский биотерапевтический журнал. 2018;17(4):81–90. DOI: 10.17650/1726-9784-2018-17-4-81-90.</mixed-citation><mixed-citation xml:lang="en">Blynskaya E. V., Tishkov S. V., Alekseyev K. V., Minaev S. V. Features pharmaceutical development lyophilisate GK-2 for parenteral use. Russian Journal of Biotherapy. 2018;17(4):81–90. (In Russ.) DOI: 10.17650/1726-9784-2018-17-4-81-90.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Береговых В. В., Спицкий О. Р. Применение подхода, основанного на рисках, для определения критических факторов при переносе технологии в производстве лекарственных средств. Вестник РАМН. 2014;69(9–10):117–122. DOI: 10.15690/vramn.v69i9-10.1140.</mixed-citation><mixed-citation xml:lang="en">Beregovykh V. V., Spitskii O. R. Application of risk-based approach for determination of critical factors in technology transfer of production of medicinal products. Annals of the Russian academy of medical sciences. 2014;69(9–10):117–122. (In Russ.) DOI: 10.15690/vramn.v69i9-10.1140.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Тишков С. В., Блынская Е. В., Алексеев К. В., Алексеев В. К. Особенности методов анализа, оценки и контроля рисков в фармацевтической разработке. Российский биотерапевтический журнал. 2023;22(1):28–41. DOI: 10.17650/1726-9784-2023-22-1-28-41.</mixed-citation><mixed-citation xml:lang="en">Tishkov S. V., Blynskaya E. V., Alekseev K. V., Alekseev V. K. Features of risk analysis, assessment and control methods in pharmaceutical development. Russian Journal of Biotherapy. 2023;22(1):28–41. (In Russ.) DOI: 10.17650/1726-9784-2023-22-1-28-41</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nikolaeva L. L., Lantsova A. V., Sanarova, E. V., Orlova O. L., Oborotov A. V., Ignatieva E. V., Shprakh Z. S., Kulbachevskaya N. Yu., Konyaeva O. I. Development of the Composition and Technology for Obtaining a Model of an Injection Form of an Indolocarbazole Derivative. Pharmaceutical Chemistry Journal. 2023;57:874–878. DOI: 10.1007/s11094-023-02962-6.</mixed-citation><mixed-citation xml:lang="en">Nikolaeva L. L., Lantsova A. V., Sanarova, E. V., Orlova O. L., Oborotov A. V., Ignatieva E. V., Shprakh Z. S., Kulbachevskaya N. Yu., Konyaeva O. I. Development of the Composition and Technology for Obtaining a Model of an Injection Form of an Indolocarbazole Derivative. Pharmaceutical Chemistry Journal. 2023;57:874–878. DOI: 10.1007/s11094-023-02962-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Игнатьева Е. В., Ярцева И. В., Шпрах З. С., Колпаксиди А. П., Дмитриева М. В., Ланцова А. В., Николаева Л. Л., Просалкова И. Р. Количественное определение N-гликозидного производного замещенного индоло[2,3a]карбазола в инновационных лекарственных формах. Российский биотерапевтический журнал. 2022;21(3):61–71. DOI: 10.17650/1726-9784-2022-21-3-61-71.</mixed-citation><mixed-citation xml:lang="en">Ignatieva E. V., Yartseva I. V., Shprakh Z. S., Kolpaksidi A. P., Dmitrieva M. V., Lantsova A. V., Nikolaeva L. L., Prosalkova I. R. Quantitative determination of the N-glycoside derivative of substituted indolo[2,3a]carbazole in innovative dosage forms. Russian Journal of Biotherapy. 2022;21(3):61–71. (In Russ.) DOI: 10.17650/1726-9784-2022-21-3-61-71.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mazumder S., Pavurala N., Manda P., Xu X., Cruz C. N., Krishnaiah Y. S. R. Quality by Design approach for studying the impact of formulation and process variables on product quality of oral disintegrating films. International Journal of Pharmaceutics. 2017;527(1–2):151–160. DOI: 10.1016/j.ijpharm.2017.05.048.</mixed-citation><mixed-citation xml:lang="en">Mazumder S., Pavurala N., Manda P., Xu X., Cruz C. N., Krishnaiah Y. S. R. Quality by Design approach for studying the impact of formulation and process variables on product quality of oral disintegrating films. International Journal of Pharmaceutics. 2017;527(1–2):151–160. DOI: 10.1016/j.ijpharm.2017.05.048.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
